BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Rojo, A. I., Buttari, B., & Cadenas, S. (2025). Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases. Redox Biology, 79, 103464. Added by: Dr. Enrique Feoli (23/09/2025, 00:09) Last edited by: Dr. Enrique Feoli (23/09/2025, 00:10) |
 |
| Resource type: Journal Article DOI: 10.1016/j.redox.2024.103464 ID no. (ISBN etc.): 2213-2317 BibTeX citation key: Rojo2025 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Homeostasis Keywords: inflammation, Model organisms, Non-communicable chronic diseases, NRF2, Oxidative stress Creators: Buttari, Cadenas, Rojo Collection: Redox Biology |
Views: 5/38
|
| Abstract |
|
Non-communicable chronic diseases (NCDs) are most commonly characterized by age-related loss of homeostasis and/or by cumulative exposures to environmental factors, which lead to low-grade sustained generation of reactive oxygen species (ROS), chronic inflammation and metabolic imbalance. Nuclear factor erythroid 2-like 2 (NRF2) is a basic leucine-zipper transcription factor that regulates the cellular redox homeostasis. NRF2 controls the expression of more than 250 human genes that share in their regulatory regions a cis-acting enhancer termed the antioxidant response element (ARE). The products of these genes participate in numerous functions including biotransformation and redox homeostasis, lipid and iron metabolism, inflammation, proteostasis, as well as mitochondrial dynamics and energetics. Thus, it is possible that a single pharmacological NRF2 modulator might mitigate the effect of the main hallmarks of NCDs, including oxidative, proteostatic, inflammatory and/or metabolic stress. Research on model organisms has provided tremendous knowledge of the molecular mechanisms by which NRF2 affects NCDs pathogenesis. This review is a comprehensive summary of the most commonly used model organisms of NCDs in which NRF2 has been genetically or pharmacologically modulated, paving the way for drug development to combat NCDs. We discuss the validity and use of these models and identify future challenges.
|